drugset

drugset / Trial / NCT00344773

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

NCT00344773 ↗

Phase 2 Completed 46 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.

Timeline

Start: 2006-03
Primary completion: 2007-12
Completion: 2007-12

Publications

Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer. 2011 Jan;71(1):65-9. doi: 10.1016/j.lungcan.2010.04.005.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefitinib	Small molecule	250 mg	Oral

Indications